Immunicom

Immunicom Inc. is developing a device-based platform for cancer treatment. Its lead therapy is designed to remove sTNF-R immune-suppressive factors to restore TNF-α antitumor activity.

The abstract describes Immunopheresis as therapeutic apheresis using the LW-02 immunoadsorption column to treat solid malignancies. It also explains how soluble TNF receptors can neutralize TNFα and promote cancer cell proliferation, survival, and chemoresistance.

The abstract describes the LW-02 Column, an immunoadsorption device developed to remove soluble TNF-α receptors from cancer patients’ plasma using apheresis.

A first-ever human clinical trial could extend or even save patients’ lives by neutralizing cancer’s ability to block a patient’s natural immune defense mechanisms, which are usually exhausted when the patient is suffering from metastatic disease

Immunicom partners with hospitals around the world to develop and commercialize therapies. The company says its technology platform can shorten immunotherapy development time, sometimes by as much as two-thirds.

Immunicom develops immunotherapies based on its Immunopheresis technology platform, which is designed to address medical needs in cancer, inflammatory, cardiovascular, renal, and autoimmune diseases.

6048 Cornerstone Ct W Suite D San Diego, CA 92121

Immunicom says its Immunopheresis is designed to empower patients while they receive cancer treatment.

The privacy policy describes how the service collects, uses, and discloses information, and explains users’ privacy rights and how the law protects them. It says personal data is used to provide and improve the service.